Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Welcome to the Lisata Therapeutics Second Quarter 2025 Financial ...

While DCTs failed to transform clinical research, artificial intelligence (AI)-powered study approaches are now fulfilling their promise within the non-interventional research space. Unified, digital ...

Q2 2025 Management View CEO Richard A. Miller stated the company's main focus remains the development of soquelitinib for atopic dermatitis, highlighting "an oral medication featuring a novel ...

Discover Trevi Therapeutics' Q2 2025 progress, featuring groundbreaking CORAL & RIVER trial data, a $204M cash position, and plans for multiple Phase ...

Consuming fewer calories is largely accepted as a way to improve health and lose weight, but a recently published study in Nature Metabolism points to ...

HistoSonics, founded in 2009, received FDA De Novo clearance in October 2023 and uses non-invasive focused ultrasound energy to mechanically destroy and liquify targeted tissue and tumors at a ...

Claiming it wants to cut waste, the Trump administration has terminated grants for research testing ways to save the health ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Relay Therapeutics beat analyst estimates for both GAAP revenue and earnings per share in Q2 2025. The company reported continued clinical advancement of its lead asset RLY-2608, with new positive ...

Shares set to fall; Fortescue says China and Fortescue are in lock step amid historic loan; Block returns to growth mode; QBE ...

AbCellera Biologics (ABCL) marks a milestone, transitioning to clinical-stage biotech with ABCL635 dosing and pipeline expansion.

Hundreds of peer-reviewed studies on marijuana and its components have been published in the first seven months of 2025, ...